Recent developments highlight Dogwood's clinical trial progress, financial activities, and operational updates through late 2026.

• Dogwood Therapeutics reported third quarter 2026 financial results and closed a $5 million private placement to support operations and clinical trials [N1].
• The company completed enrollment in the Halneuron Phase 2b chemotherapy-induced neuropathic pain trial, with topline data due in November 2026 [N2].
• Dogwood was noted in biotech market coverage as a focus company amid ongoing clinical developments [N3].
• The company neared the Phase 2b readout for Halneuron neuropathic pain treatment as of September 2026 [N4].
• Interim Phase 2b trial data showed pain relief separation for Halneuron, indicating potential efficacy [N5].
• Dogwood regained Nasdaq compliance in April 2025, ensuring continued listing and access to capital markets [N7].
• The company initiated the Phase 2b trial for Halneuron in chemotherapy-induced neuropathic pain in early 2025 and has since progressed dosing and enrollment [N8].

Dogwood's advancement of Halneuron® through Phase 2b trials with completed enrollment and interim positive pain relief data suggests potential clinical validation of its approach. The company's ability to secure funding through private placements and maintain Nasdaq compliance supports operational continuity. Licensing agreements for additional formulations expand its pipeline potential. Positive clinical outcomes could enhance its position in the neuropathic pain treatment market.

Dogwood faces risks typical of clinical-stage biotech companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company reported net losses and relies on external financing to fund operations, which may dilute shareholders or constrain resources. Potential asset loss and financial risks related to contractual obligations such as the Sealbond repurchase option add to financial uncertainty. Failure to demonstrate clinical efficacy or secure additional funding could impede progress.

Dogwood Therapeutics' moat is primarily based on its proprietary clinical-stage assets targeting neuropathic pain, including Halneuron®, which is in advanced Phase 2b trials. The company's licensing agreements for novel formulations and its specialized focus on chemotherapy-induced neuropathic pain provide a niche positioning. However, as a clinical-stage biotech without approved products, its moat depends on successful clinical development and regulatory approvals, which remain uncertain and competitive.

• Clinical Trial Risk: The success of Dogwood's lead product candidate Halneuron® depends on positive outcomes from ongoing Phase 2b trials, which are inherently uncertain.
• Financial Risk: The company reported net losses and depends on equity offerings and financing to fund operations, which may impact liquidity and shareholder dilution.
• Regulatory and Compliance Risk: Dogwood must maintain regulatory compliance and Nasdaq listing standards to continue operations and access capital markets.
• Contractual and Asset Risk: Potential asset loss and financial risks exist related to the Sealbond repurchase option and other contractual obligations.

• Dogwood Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropathic pain and other conditions.
• The company is conducting a Phase 2b clinical trial for Halneuron®, a treatment for chemotherapy-induced neuropathic pain (CINP).
• Enrollment in the Halneuron Phase 2b CINP trial was completed as of September 2026, with topline data due in November 2026.
• Interim Phase 2b trial data showed pain relief separation for Halneuron, indicating potential efficacy.
• Dogwood has initiated dosing in the Phase 2b trial for Halneuron® as early as January 2025.
• The company has secured licenses to develop formulations such as Serpin Pharma's IV formulation of SP16.
• Dogwood has conducted private placements and direct offerings to fund operations and clinical trials, including a $5 million private placement reported in November 2026 and a $4.8 million direct offering in March 2025.
• The company reported a net loss of approximately $4.88 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.14 per share.
• As of September 30, 2026, Dogwood held approximately $4.95 million in cash and cash equivalents, with current assets of about $6.04 million and current liabilities of approximately $2.17 million, resulting in a current ratio of 2.78 and a cash ratio of 2.28.
• Dogwood regained Nasdaq compliance as of April 2025.
• The company has faced potential asset loss and financial risks related to a Sealbond repurchase option.
• Dogwood has reported research findings on IMC-2 treatment reducing long-COVID related fatigue and sleep disturbance.
• The number of outstanding shares as of March 10, 2026, was approximately 33.4 million shares.
• Dogwood is classified as a smaller reporting company and is not a shell company.
• The company has maintained ongoing equity incentive plans and has engaged in debt-to-equity exchanges to strengthen its financial position for clinical trials.